Rafestin-Oblin ME - Search Results

1

Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.

Petit-Topin I, Turque N, Fagart J, Fay M, Ulmann A, Gainer E, Rafestin-Oblin ME. Petit-Topin I, et al. Mol Pharmacol. 2009 Jun;75(6):1317-24. doi: 10.1124/mol.108.054312. Epub 2009 Mar 16. Mol Pharmacol. 2009. PMID: 19289570

2

11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.

Rafestin-Oblin ME, Fagart J, Souque A, Seguin C, Bens M, Vandewalle A. Rafestin-Oblin ME, et al. Mol Pharmacol. 2002 Dec;62(6):1306-13. doi: 10.1124/mol.62.6.1306. Mol Pharmacol. 2002. PMID: 12435797

3

The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.

Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME. Fagart J, et al. Mol Pharmacol. 2005 May;67(5):1714-22. doi: 10.1124/mol.104.010710. Epub 2005 Feb 16. Mol Pharmacol. 2005. PMID: 15716462

4

The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor.

Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A. Takeda AN, et al. Mol Pharmacol. 2007 Feb;71(2):473-82. doi: 10.1124/mol.106.031112. Epub 2006 Nov 14. Mol Pharmacol. 2007. PMID: 17105867

5

Structural basis of spirolactone recognition by the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME. Huyet J, et al. Mol Pharmacol. 2007 Sep;72(3):563-71. doi: 10.1124/mol.107.036459. Epub 2007 Jun 14. Mol Pharmacol. 2007. PMID: 17569793

6

Structural determinants of ligand binding to the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Rafestin-Oblin ME, Fagart J. Huyet J, et al. Among authors: rafestin oblin me. Mol Cell Endocrinol. 2012 Mar 24;350(2):187-95. doi: 10.1016/j.mce.2011.07.035. Epub 2011 Jul 25. Mol Cell Endocrinol. 2012. PMID: 21820032 Review.

7

A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation.

Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hétuin D, Formstecher P, Rafestin-Oblin ME, Idziorek T. Dezitter X, et al. Among authors: rafestin oblin me. Mol Pharmacol. 2014 Feb;85(2):226-36. doi: 10.1124/mol.113.085860. Epub 2013 Nov 13. Mol Pharmacol. 2014. PMID: 24225022

8

Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity.

Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin ME, Farman N. Bocchi B, et al. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):239-44. doi: 10.1016/s0960-0760(03)00036-0. J Steroid Biochem Mol Biol. 2003. PMID: 12711009

9

Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.

Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, Rafestin-Oblin ME. Pinon GM, et al. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):181-8. doi: 10.1016/j.mce.2003.10.053. Mol Cell Endocrinol. 2004. PMID: 15134816

10

Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.

Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME. Fagart J, et al. Nat Struct Mol Biol. 2005 Jun;12(6):554-5. doi: 10.1038/nsmb939. Epub 2005 May 22. Nat Struct Mol Biol. 2005. PMID: 15908963

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters